These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

988 related articles for article (PubMed ID: 9393755)

  • 1. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
    Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
    Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Saï-Maurel C; Campion L; Faivre-Chauvet A; Mirallié E; Chérel M; Supiot S; Barbet J; Chatal JF; Thédrez P
    Mol Cancer Ther; 2002 Feb; 1(4):267-74. PubMed ID: 12467222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of combined radioimmunotherapy and chemotherapy for treatment of medullary thyroid cancer.
    Stein R; Juweid M; Zhang CH; Goldenberg DM
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3199s-3206s. PubMed ID: 10541364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs.
    Stein R; Juweid M; Mattes MJ; Goldenberg DM
    Cancer Biother Radiopharm; 1999 Feb; 14(1):37-47. PubMed ID: 10850286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
    Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
    Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
    Stein R; Chen S; Reed L; Richel H; Goldenberg DM
    Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting and initial radioimmunotherapy of medullary thyroid carcinoma with 131I-labeled monoclonal antibodies to carcinoembryonic antigen.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Rubin AD; Hanley D; Herskovic T; Markowitz A; Siegel J; Goldenberg DM
    Cancer Res; 1995 Dec; 55(23 Suppl):5946s-5951s. PubMed ID: 7493375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
    Stein R; Goldenberg DM
    Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.
    Behr TM; Béhé M; Löhr M; Sgouros G; Angerstein C; Wehrmann E; Nebendahl K; Becker W
    Eur J Nucl Med; 2000 Jul; 27(7):753-65. PubMed ID: 10952487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study.
    Behr TM; Salib AL; Liersch T; Béhé M; Angerstein C; Blumenthal RD; Fayyazi A; Sharkey RM; Ringe B; Becker H; Wörmann B; Hiddemann W; Goldenberg DM; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3232s-3242s. PubMed ID: 10541369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic efficacy and dose-limiting toxicity of Auger-electron vs. beta emitters in radioimmunotherapy with internalizing antibodies: evaluation of 125I- vs. 131I-labeled CO17-1A in a human colorectal cancer model.
    Behr TM; Sgouros G; Vougiokas V; Memtsoudis S; Gratz S; Schmidberger H; Blumenthal RD; Goldenberg DM; Becker W
    Int J Cancer; 1998 May; 76(5):738-48. PubMed ID: 9610734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.
    Behr TM; Sharkey RM; Sgouros G; Blumenthal RD; Dunn RM; Kolbert K; Griffiths GL; Siegel JA; Becker WS; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2591-610. PubMed ID: 9406714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental studies on the role of antibody fragments in cancer radio-immunotherapy: Influence of radiation dose and dose rate on toxicity and anti-tumor efficacy.
    Behr TM; Memtsoudis S; Sharkey RM; Blumenthal RD; Dunn RM; Gratz S; Wieland E; Nebendahl K; Schmidberger H; Goldenberg DM; Becker W
    Int J Cancer; 1998 Aug; 77(5):787-95. PubMed ID: 9688314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies.
    Juweid M; Sharkey RM; Behr T; Swayne LC; Herskovic T; Pereira M; Rubin AD; Hanley D; Dunn R; Siegel J; Goldenberg DM
    J Nucl Med; 1996 Jun; 37(6):905-11. PubMed ID: 8683309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma.
    Salaun PY; Bodet-Milin C; Frampas E; Oudoux A; Saï-Maurel C; Faivre-Chauvet A; Barbet J; Paris F; Kraeber-Bodéré F
    Cancer; 2010 Feb; 116(4 Suppl):1053-8. PubMed ID: 20127950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies.
    Blumenthal RD; Sharkey RM; Haywood L; Natale AM; Wong GY; Siegel JA; Kennel SJ; Goldenberg DM
    Cancer Res; 1992 Nov; 52(21):6036-44. PubMed ID: 1394228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.